SymBio Pharmaceuticals Limited (TYO:4582)
69.00
-9.00 (-11.54%)
Nov 20, 2026, 3:30 PM JST
SymBio Pharmaceuticals Revenue
SymBio Pharmaceuticals had revenue of 252.14M JPY in the quarter ending September 30, 2026, a decrease of -22.22%. This brings the company's total for the last twelve months to 1.06B, down -30.58% year-over-year. In the year 2025, SymBio Pharmaceuticals had annual revenue of 1.31B, down -46.70%. That makes SymBio Pharmaceuticals the 39,006th largest company in the world by revenue and 3,785th in Japan.
Revenue (ttm)
1.06B
Revenue Growth
-30.58%
P/S Ratio
5.50
Revenue / Employee
11.64M
Employees
91
Market Cap
5.83B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.31B | -1.15B | -46.70% |
| Dec 31, 2024 | 2.45B | -3.14B | -56.13% |
| Dec 31, 2023 | 5.59B | -4.42B | -44.15% |
| Dec 31, 2022 | 10.01B | 1.75B | 21.21% |
| Dec 31, 2021 | 8.26B | 5.27B | 176.42% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Ohki Healthcare Holdings | 363.02B |
| Cawachi | 283.28B |
| YAKUODO HOLDINGS | 170.75B |
| Medical System Network | 135.21B |
| Satudora Holdings | 100.33B |
| Pharmarise Holdings | 70.00B |
| Astena Holdings | 69.51B |
| Miahelsa Holdings | 25.32B |